Shanghai - Delayed Quote CNY

DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)

Compare
14.30 -0.42 (-2.85%)
At close: June 28 at 3:00 PM GMT+8
Loading Chart for 603233.SS
DELL
  • Previous Close 14.72
  • Open 14.70
  • Bid 14.29 x --
  • Ask 14.30 x --
  • Day's Range 14.28 - 14.82
  • 52 Week Range 14.28 - 30.22
  • Volume 12,630,249
  • Avg. Volume 8,480,647
  • Market Cap (intraday) 16.286B
  • Beta (5Y Monthly) 0.20
  • PE Ratio (TTM) 16.63
  • EPS (TTM) 0.86
  • Earnings Date --
  • Forward Dividend & Yield 0.31 (2.17%)
  • Ex-Dividend Date Jun 21, 2024
  • 1y Target Est 31.43

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. It provides Chinese and western patent medicines, ginseng tonic medicinal materials and Chinese herbal pieces, health care products, medical equipment, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.

www.dslyy.com

45,466

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603233.SS

View More

Performance Overview: 603233.SS

Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

603233.SS
41.41%
SSE Composite Index
0.25%

1-Year Return

603233.SS
48.01%
SSE Composite Index
6.96%

3-Year Return

603233.SS
57.74%
SSE Composite Index
17.74%

5-Year Return

603233.SS
28.05%
SSE Composite Index
0.98%

Compare To: 603233.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603233.SS

View More

Valuation Measures

Annual
As of 6/28/2024
  • Market Cap

    16.29B

  • Enterprise Value

    17.70B

  • Trailing P/E

    16.63

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.67

  • Price/Book (mrq)

    2.23

  • Enterprise Value/Revenue

    0.70

  • Enterprise Value/EBITDA

    11.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.22%

  • Return on Assets (ttm)

    4.50%

  • Return on Equity (ttm)

    14.46%

  • Revenue (ttm)

    25.34B

  • Net Income Avi to Common (ttm)

    1.07B

  • Diluted EPS (ttm)

    0.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.4B

  • Total Debt/Equity (mrq)

    80.51%

  • Levered Free Cash Flow (ttm)

    3.17B

Research Analysis: 603233.SS

View More

Company Insights: 603233.SS

Research Reports: 603233.SS

View More

People Also Watch